Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Biocon is currently trading at Rs. 428.70, up by 3.50 points or 0.82% from its previous closing of Rs. 425.20 on the BSE.
The scrip opened at Rs. 425.20 and has touched a high and low of Rs. 430.50 and Rs. 420.30 respectively. So far 59073 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 553.70 on 04-Jul-2014 and a 52 week low of Rs. 402.45 on 07-Jan-2015.
Last one week high and low of the scrip stood at Rs. 460.15 and Rs. 421.65 respectively. The current market cap of the company is Rs. 8484.00 crore.
The promoters holding in the company stood at 61.02% while Institutions and Non-Institutions held 19.10% and 19.87% respectively.
Biocon, Asia’s premier biotechnology company, has made clinical progress in its partnered programs with Mylan. The partnership has a strong portfolio of generic insulin analogs and biosimilars including Monoclonal Antibodies (MAbs) and recombinant proteins at various stages of development.
Two molecules Pegfilgrastim (PEG-G-CSF) and Adalimumab have entered global Phase 3 clinical trials. While the PEG-G-CSF trial is well underway the Adalimumab trial has been recently initiated. In addition, the Phase 3 global clinical trial for Trastuzumab is progressing in more than 100 sites around the world. An initial ROW focused Phase 3 trial for Bevacizumab is also underway.
Further, two global clinical trials for generic Insulin Glargine initiated in 2014, have also made significant progress. The patient recruitment for Type-1 diabetes study has been completed ahead of schedule, while the recruitment for Type-2 diabetes study is expected to be completed by July 2015.
Biocon is India’s largest and Asia’s leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.75 |
| Dr. Reddys Lab | 5810.00 |
| Cipla | 1408.00 |
| Zydus Lifesciences | 1031.60 |
| Lupin | 1664.50 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
